Interv Akut Kardiol. 2007;6(2):56-60

Heart failure with preserved ejection fraction

Vojtěch Melenovský, Jiří Kettner
Klinika kardiologie, Institut klinické a experimentální medicíny, Praha

It has been increasingly recognized that half of patients hospitalized for heart failure has relatively preserved systolic function of the left ventricle. Prevalence of this type of heart failure is increasing and long-term prognosis is similarly dismal as in systolic dysfunction. In its typical form, this disease occurs in older patients, more in females, with long history of arterial hypertension and/or diabetes, who have concentric left ventricular hypertrophy or remodeling, dilated left atrium and abnormalities of diastolic ventricular filling. Despite so frequent, pathophysiology of this disease is not completely elucidated. Besides abnormal diastolic ventricular properties and decreased contractile reserve, other extraventricular mechanisms are equally relevant, such are increased stiffness of large arteries, abnormal mechanical function of left atrium and abnormal autonomic cardiovascular control. Clinical presentation of this condition is characterized by rapidly developing pulmonary congestion, increased systemic arterial blood pressure and preserved cardiac output and ejection fraction. Acute therapy consists of maintaining adequate oxygenation, sedation, administration of diuretics and most importantly, vasodilatators. Long term care consists of handling fluid retention with diuretics and meticulous control of hypertension, preferably with drugs with proven capacity to induce regression of left ventricular hypertrophy. It can be expected that current intensive research of this condition will identify critical mechanisms responsible for the pathophysiology, which will ultimately lead to more specific and causal therapies.

Keywords: heart failure, ejection fraction, diastolic dysfunction, arterial hypertension, left ventricular hypertrophy

Published: June 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Melenovský V, Kettner J. Heart failure with preserved ejection fraction. Interv Akut Kardiol. 2007;6(2):56-60.
Download citation

References

  1. Lenzen MJ, Scholte op Reimer WJ, Boersma E et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J 2004; 25(14):1214-1220. Go to original source... Go to PubMed...
  2. Yancy CW, Lopatin M, Stevenson LW et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006; 47(1):76-84. Go to original source... Go to PubMed...
  3. Liao L, Jollis JG, Anstrom KJ et al. Costs for heart failure with normal vs reduced ejection fraction. Arch Intern Med 2006; 166(1):112-118. Go to original source... Go to PubMed...
  4. Owan TE, Hodge DO, Herges RM et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355(3):251-259. Go to original source... Go to PubMed...
  5. Swedberg K, Cleland J, Dargie H et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26(11):1115-1140. Go to original source... Go to PubMed...
  6. Gandhi SK, Powers JC, Nomeir AM et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 2001; 344(1):17-22. Go to original source... Go to PubMed...
  7. Heart Failure Society Of America. Evaluation and management of patients with heart failure and preserved left ventricular ejection fraction. J Card Fail 2006; 12(1):e80-e85. Go to original source... Go to PubMed...
  8. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004; 350(19):1953-1959. Go to original source... Go to PubMed...
  9. Kawaguchi M, Hay I, Fetics B et al. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation 2003; 107(5):714-720. Go to original source... Go to PubMed...
  10. Redfield MM, Jacobsen SJ, Burnett JC, Jr. et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289(2):194-202. Go to original source... Go to PubMed...
  11. Yu CM, Lin H, Yang H et al. Progression of systolic abnormalities in patients with, ,isolated" diastolic heart failure and diastolic dysfunction. Circulation 2002; 105(10):1195-1201. Go to original source... Go to PubMed...
  12. Borlaug BA, Melenovsky V, Russell SD et al. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 2006; 114(20):2138-2147. Go to original source... Go to PubMed...
  13. Melenovsky V, Borlaug BA, Rosen B et al. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol 2007; 49(2):198-207. Go to original source... Go to PubMed...
  14. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 2005; 25(5):932-943. Go to original source... Go to PubMed...
  15. Leite-Moreira AF, Correia-Pinto J, Gillebert TC. Afterload induced changes in myocardial relaxation: a mechanism for diastolic dysfunction. Cardiovasc Res 1999; 43(2):344-353. Go to original source... Go to PubMed...
  16. Chen CH, Nakayama M, Nevo E et al. Coupled systolic-ventricular and vascular stiffening with age: implications for pressure regulation and cardiac reserve in the elderly. J Am Coll Cardiol 1998; 32(5):1221-1227. Go to original source... Go to PubMed...
  17. Nieminen MS, Bohm M, Cowie MR et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26(4):384-416. Go to original source... Go to PubMed...
  18. Bruch C, Grude M, Muller J et al. Usefulness of tissue Doppler imaging for estimation of left ventricular filling pressures in patients with systolic and diastolic heart failure. Am J Cardiol 2005; 95(7):892-895. Go to original source... Go to PubMed...
  19. Maisel AS, McCord J, Nowak RM et al. Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 2003; 41(11):2010-2017. Go to original source... Go to PubMed...
  20. Cotter G, Metzkor E, Kaluski E et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 1998; 351(9100):389-393. Go to original source... Go to PubMed...
  21. Špinar J, Janský P, Kettner J et al. Doporučení pro diagnostiku a léčbu akutního srdečního selhání. Cor Vasa 48 (1), K3-K31. 2007.
  22. Peter JV, Moran JL, Phillips-Hughes J et al. Effect of non-invasive positive pressure ventilation (NIPPV) on mortality in patients with acute cardiogenic pulmonary oedema: a meta-analysis. Lancet 2006; 367(9517):1155-1163. Go to original source... Go to PubMed...
  23. Špinar J, Hradec J, Meluzín J. Doporučení pro diagnostiku a léčbu chronického srdečního selhání ČKS 2006. Cor Vasa 49(1), K5-K34. 2007.
  24. Devereux RB, Dahlof B, Gerdts E et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004; 110(11):1456-1462. Go to original source... Go to PubMed...
  25. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362(9386):777-781. Go to original source... Go to PubMed...
  26. Cleland JG, Tendera M, Adamus J et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27(19):2338-2345. Go to original source... Go to PubMed...
  27. Carson P, Massie BM, McKelvie R et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Card Fail 2005; 11(8):576-585. Go to original source... Go to PubMed...
  28. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997; 336(8):525-533.
  29. Flather MD, Shibata MC, Coats AJ et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26(3):215-225. Go to original source... Go to PubMed...
  30. Kass DA, Bronzwaer JG, Paulus WJ. What mechanisms underlie diastolic dysfunction in heart failure? Circ Res 2004; 94(12):1533-1542. Go to original source... Go to PubMed...
  31. Hundley WG, Kitzman DW, Morgan TM et al. Cardiac cycle-dependent changes in aortic area and distensibility are reduced in older patients with isolated diastolic heart failure and correlate with exercise intolerance. J Am Coll Cardiol 2001; 38(3):796-802. Go to original source... Go to PubMed...
  32. Arques S, Ambrosi P, Gelisse R et al. Hypoalbuminemia in elderly patients with acute diastolic heart failure. J Am Coll Cardiol 2003; 42(4):712-716. Go to original source... Go to PubMed...




Interventional Cardiology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.